MedPath

Lyme Test Indication Combinations (LyTIC) Study

Terminated
Conditions
Lyme Disease
Interventions
Diagnostic Test: PCR based assay
Diagnostic Test: Serology based assay
Diagnostic Test: Tcell based assay
Registration Number
NCT03201042
Lead Sponsor
Oxford Immunotec
Brief Summary

To establish performance of individual tests and combinations of tests (serological, molecular and cellular tests) in early Lyme infection diagnosis

Detailed Description

The present study aims to investigate the performance characteristics of both established and new assays for Borrelia burgdorferi infection and to assess the relative performance of appropriate combinations of these tests. The study will also investigate the effect of the time course of the infection and its treatment on the outcomes for the various tests. Polymerase Chain Reaction(PCR), serology and T cell based tests will be performed. In addition, tests for Babesia, Anaplasma, Ehrlichia and Rickettsia will also be performed as these pathogens can be carried by the same tick that carries Borrelia and may result in coinfection.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
410
Inclusion Criteria
  • Cohort 1a (typical EM and intention to treat):

Inclusion

  1. Documented new onset Lyme disease EM rash (single or multiple) with photographic evidence provided to Oxford Immunotec.
  2. Patient must be able to provide blood sample at the initial visit (prior to treatment initiation) and subsequent samples according to the schedule.
  3. Patients 5 years of age or older, with a minimum weight of 40 pounds.
  4. Patient able to read English and to give consent to study participation.
  5. If patient is younger than 18 years of age a legally authorized representative must provide consent.

Cohort 1b (no typical EM; Lyme disease symptoms; intention to treat):

Inclusion

  1. Patients with suspected Lyme disease, based on physician's examination, where the physician has the intention to treat for Lyme disease (i.e. patients who following initial examination were prescribed treatment for Lyme disease).
  2. Documented new onset of Lyme disease symptoms without a typical EM rash or with no rash. If a rash is present, photographic evidence must be provided.
  3. Patient must be able to provide blood sample at the initial visit (prior to treatment initiation) and subsequent samples according to the schedule.
  4. Patients 5 years of age or older, with a minimum weight of 40 pounds.
  5. Patient able to read English and to give consent to study participation.
  6. If patient is younger than 18 years of age a legally authorized representative must provide consent.

Cohort 2 (Healthy subjects):

Inclusion

  1. Subjects 5 years of age or older, with a minimum weight of 40 pounds.
  2. Subjects never diagnosed with any tick borne disease including Lyme disease
  3. Subjects able to read English and to give consent to study participation.
  4. If subject is younger than 18 years of age a legally authorized representative must provide consent.
Exclusion Criteria
  • Exclusion Cohort 1a (typical EM and intention to treat):

    1. Patients with Lyme-like symptoms lasting longer than 1 month prior to study enrolment.
    2. Patients receiving treatment for any tick borne disease (including Lyme disease) prior to enrolment.
    3. Patients who received a Lyme vaccination.
    4. Patients with anemia defined as a serum hemoglobin <10gm/dL.
    5. Patients who are participating in, or plan to participate in, any investigational drug study.
    6. Patients who are considered unsuitable for the study by the Investigator.

Cohort 1b (no typical EM; Lyme disease symptoms; intention to treat):

  1. Patients with Lyme-like symptoms lasting longer than 1 month prior to study enrolment.
  2. Patients receiving treatment for any tick borne disease (including Lyme disease) prior to enrolment.
  3. Patients who received a Lyme vaccination.
  4. Patients with anemia defined as a serum hemoglobin <10gm/dL.
  5. Patients who are participating in, or plan to participate in, any investigational drug study.
  6. Patients who are considered unsuitable for the study by the Investigator.

Cohort 2 (Healthy subjects):

Exclusion

  1. Subjects with a history of tick bite
  2. Subjects with past or current tick borne disease diagnosis
  3. Subjects at risk for tick borne diseases including Lyme disease
  4. Subjects residing in endemic regions for tick borne diseases: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia and Wisconsin.
  5. Subjects who have ever visited non-urban areas of endemic regions for tick borne diseases: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia and Wisconsin.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
1a:Lyme patients- Erythema Migrans(EM)rash presentPCR based assayPatients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
1a:Lyme patients- Erythema Migrans(EM)rash presentSerology based assayPatients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
1b:Lyme patients no typical EMSerology based assayPatients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
Cohort 2: healthy controlsPCR based assayPatients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
1a:Lyme patients- Erythema Migrans(EM)rash presentTcell based assayPatients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
1b:Lyme patients no typical EMPCR based assayPatients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
1b:Lyme patients no typical EMTcell based assayPatients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
Cohort 2: healthy controlsSerology based assayPatients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
Cohort 2: healthy controlsTcell based assayPatients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
Primary Outcome Measures
NameTimeMethod
Sample Data AnalysisTests at different time points post inital presentation will be evaluated through study completion, an average of 1 year.

The results will be used to calculate performance, including sensitivity and specificity of the tests under evaluation. The utility of these tests at different time points post initial presentation will be evaluated.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (59)

Circle CARE Center

🇺🇸

Norwalk, Connecticut, United States

Collegeville Family Practice

🇺🇸

Collegeville, Pennsylvania, United States

Acadia Clinical Research

🇺🇸

Bangor, Maine, United States

Klein & Associates, MD, PA

🇺🇸

Hagerstown, Maryland, United States

MD Medical Research, Inc.

🇺🇸

Oxon Hill, Maryland, United States

NECCR Primacare Research,LLC

🇺🇸

Fall River, Massachusetts, United States

Rapid Medical Research

🇺🇸

Cleveland, Ohio, United States

Centennial Medical Group

🇺🇸

Eldridge, Maryland, United States

Orthopaedic Foundation for Active Lifestyles, Inc

🇺🇸

Stamford, Connecticut, United States

Metromedic Walk In

🇺🇸

New Bedford, Massachusetts, United States

Coastal Connecticut Research

🇺🇸

New London, Connecticut, United States

Advance Clinical Research

🇺🇸

Meridian, Idaho, United States

Private Practice-Johnathan Liebowitz

🇺🇸

Brooklyn, New York, United States

NY Arthritis Clinic

🇺🇸

Brooklyn, New York, United States

Asthma and Allergy Institute of MI

🇺🇸

Clinton Township, Michigan, United States

Brandywine Clinic

🇺🇸

Downingtown, Pennsylvania, United States

Integrative Health Center of Maine

🇺🇸

Portland, Maine, United States

Rockville Internal Medicine Group

🇺🇸

Rockville, Maryland, United States

Delaware Integrated Medicine

🇺🇸

Georgetown, Delaware, United States

Andrea Gaito

🇺🇸

Basking Ridge, New Jersey, United States

Paradigm Clinical Research

🇺🇸

Redding, California, United States

Pinnacle Research

🇺🇸

Sartell, Minnesota, United States

Brookside Family Health Care

🇺🇸

Hinesburg, Vermont, United States

Eastern Research, Inc.

🇺🇸

Hialeah, Florida, United States

South Florida Clinical Trials SFCT, A member of the Alliance, Inc.

🇺🇸

Hialeah, Florida, United States

Pediatric Medical Associates of NTN/ABG

🇺🇸

East Norriton, Pennsylvania, United States

Clinical Pharmacology Study Group

🇺🇸

Worcester, Massachusetts, United States

Cape Cod Hospital

🇺🇸

Hyannis, Massachusetts, United States

Modern Medical

🇺🇸

Brooklyn, New York, United States

The Research Institute

🇺🇸

Springfield, Massachusetts, United States

NECCR Primacare Research, LLC

🇺🇸

Portsmouth, Rhode Island, United States

John T. Mather Hospital

🇺🇸

Port Jefferson, New York, United States

Altoona Center for Clinical Research

🇺🇸

Duncansville, Pennsylvania, United States

Adirondack Medical Research Center

🇺🇸

Glens Falls, New York, United States

Detweiler Family Practice

🇺🇸

Lansdale, Pennsylvania, United States

Safe Harbor Clinical Research

🇺🇸

East Providence, Rhode Island, United States

Private Practice-David Wurwitz

🇺🇸

Flushing, New York, United States

NYCT, A member of Alliance, Inc.

🇺🇸

New York, New York, United States

Buckeye Health and Research

🇺🇸

Columbus, Ohio, United States

Bally Medical Group

🇺🇸

Barto, Pennsylvania, United States

Oakland Medical Research

🇺🇸

Troy, Michigan, United States

MAffiliated Medical Associates

🇺🇸

Florham Park, New Jersey, United States

Toledo Institute of Clinical Research

🇺🇸

Toledo, Ohio, United States

Liberty Family Practice/Square 1

🇺🇸

Erie, Pennsylvania, United States

Regional Clinical Research, Inc.

🇺🇸

Endwell, New York, United States

Suburban Research Assoc.

🇺🇸

Media, Pennsylvania, United States

Boyertown Medical Assoc.

🇺🇸

Boyertown, Pennsylvania, United States

Spring-Ford Family Practice

🇺🇸

Royersford, Pennsylvania, United States

Atascosa Clinical Trial

🇺🇸

Lytle, Texas, United States

Burke Internal Medicine

🇺🇸

Burke, Virginia, United States

Exemplar Research

🇺🇸

Morgantown, West Virginia, United States

Mid Hudson Medical Research

🇺🇸

Newburgh, New York, United States

Green and Seidner Family Practice

🇺🇸

Lansdale, Pennsylvania, United States

Brookside Family Practice and Pediatrics

🇺🇸

Pottstown, Pennsylvania, United States

Millennium Clincial Trials

🇺🇸

Arlington, Virginia, United States

The Education and Research Foundation, Inc.

🇺🇸

Lynchburg, Virginia, United States

Ocean State Clinical Research

🇺🇸

Lincoln, Rhode Island, United States

Manassas Clinical Research Center

🇺🇸

Manassas, Virginia, United States

South Coast Research Center

🇺🇸

Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath